Effects of Ferulic Acid and Angelica archangelica Extract (Feru-guard ®) on Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Prospective Trial
| Autor: | Shunji Yasaki, Takeshi Tabira, Chiaki Kudoh, Ryu Ubagai, Tomokatsu Hori |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Short Communication Population Angelica archangelica Placebo Gastroenterology Ferulic acid Double blind 03 medical and health sciences chemistry.chemical_compound mild cognitive impairment 0302 clinical medicine Internal medicine medicine Cognitive impairment education 030304 developmental biology double-blind randomized trial 0303 health sciences education.field_of_study biology business.industry General Neuroscience Repeated measures design biology.organism_classification Psychiatry and Mental health Clinical Psychology chemistry Prospective trial dietary supplement Geriatrics and Gerontology business human activities 030217 neurology & neurosurgery dementia ferulic acid |
| Zdroj: | Journal of Alzheimer's Disease Reports |
| ISSN: | 2542-4823 |
| Popis: | We conducted a multicenter, randomized, double-blind, placebo-controlled prospective trial examining a supplement containing ferulic acid and Angelica archangelica extract (Feru-guard ®) for mild cognitive impairment (MCI). In the intention-to-treat population, Mini-Mental State Examination (MMSE) scores were significantly better at 24 weeks (p = 0.041) in the active group. In the per protocol population, MMSE was significantly better in the active group at 24 weeks (p = 0.008), and mixed effect models for repeated measures (MMRM) showed significant difference (p = 0.016). ADAS-Jcog was significantly better at 24 (p = 0.035) and 48 weeks (p = 0.015) in the active group, and MMRM was significant (p = 0.031). Thus, Feru-guard ® may be useful for MCI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|